Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. As with many other companies Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) makes use of debt. But is this debt a concern to shareholders?

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Why Does Debt Bring Risk?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. When we examine debt levels, we first consider both cash and debt levels, together.

How Much Debt Does Cumberland Pharmaceuticals Carry?

The image below, which you can click on for greater detail, shows that Cumberland Pharmaceuticals had debt of US$5.24m at the end of September 2025, a reduction from US$16.1m over a year. But on the other hand it also has US$15.2m in cash, leading to a US$9.96m net cash position.

How Healthy Is Cumberland Pharmaceuticals' Balance Sheet?

The latest balance sheet data shows that Cumberland Pharmaceuticals had liabilities of US$24.3m due within a year, and liabilities of US$15.8m falling due after that. On the other hand, it had cash of US$15.2m and US$10.4m worth of receivables due within a year. So it has liabilities totalling US$14.5m more than its cash and near-term receivables, combined.

While this might seem like a lot, it is not so bad since Cumberland Pharmaceuticals has a market capitalization of US$33.8m, and so it could probably strengthen its balance sheet by raising capital if it needed to. But we definitely want to keep our eyes open to indications that its debt is bringing too much risk. Despite its noteworthy liabilities, Cumberland Pharmaceuticals boasts net cash, so it's fair to say it does not have a heavy debt load! The balance sheet is clearly the area to focus on when you are analysing debt. But you can't view debt in total isolation; since Cumberland Pharmaceuticals will need earnings to service that debt. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

See our latest analysis for Cumberland Pharmaceuticals

In the last year Cumberland Pharmaceuticals wasn't profitable at an EBIT level, but managed to grow its revenue by 12%, to US$41m. We usually like to see faster growth from unprofitable companies, but each to their own.

So How Risky Is Cumberland Pharmaceuticals?

Although Cumberland Pharmaceuticals had an earnings before interest and tax (EBIT) loss over the last twelve months, it generated positive free cash flow of US$6.7m. So although it is loss-making, it doesn't seem to have too much near-term balance sheet risk, keeping in mind the net cash. Until we see some positive EBIT, we're a bit cautious of the stock, not least because of the rather modest revenue growth. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. We've identified 1 warning sign with Cumberland Pharmaceuticals , and understanding them should be part of your investment process.

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.